The Latest Breaking News on Pharma

Driven by a revamped drug portfolio, AstraZeneca is expected to report revenues of $10.7bn in its latest quarterly results

Canada’s Families Minister Karina Gould reacted to the US legal battle over mifepristone the day before the US Supreme Court ruling

WASHINGTON — The U.S. Supreme Court blocked a Texas judge’s restrictions on a widely used abortion pill from taking effect, keeping the drug fully available while a legal fight goes forward.

Federal judge in Texas ruled in early April to suspend FDA-approved mifepristone used in more than half of abortions in US

The healthcare industry should thrive with accelerated breakthrough developments and a growing market for telemedicine and personalized medicines. Moreover, given the lingering macroeconomic headwinds, fundamentally strong healthcare stocks, Amgen (AMGN), and Otsuka Holdings (OTSKY) showing Stability with A and B POWR Ratings could be ideal buys. Read more.

The biopharmaceutical industry has been grappling with various challenges, including inflation, the Fed’s hawkish stance, and new regulatory concerns. Hence, it could be wise to avoid Syndax Pharmaceuticals (SNDX), Senseonics Holdings (SENS), and Sio Gene Therapies (SIOX) due to their bleak fundamentals. Keep reading….

Coupled with fears about an economic downturn, several other headwinds could keep the biotechnology industry under significant pressure. Given this backdrop, fundamentally weak biotech stocks Day One Biopharmaceuticals (DAWN), Northwest Biotherapeutics (NWBO), and Ocugen (OCGN), with bearish momentum, could be avoided in April. Read on….

WASHINGTON — The Supreme Court gave itself more time on a decision expected Wednesday about a commonly used abortion drug, extending until Friday a temporary pause on a lower court ruling that would restrict availability of mifepristone.

A generic-mifepristone maker sued the U.S. Food and Drug Administration to protect access to the medical abortion pill amid a welter of litigation stretching from Texas to Washington.

The court has given itself until Friday to rule on whether to allow restrictions to take effect on mifepristone as legal challenges to its FDA approval continue.

GenBioPro, which makes a generic form of mifepristone, is suing the FDA seeking to preserve access to the drug amidst ongoing federal litigation.